Summary:
- Bristol-Myers Squibb has announced the topline results from a Phase 3 clinical trial called ARISE, which evaluated a new drug combination called Cobenfy (xanomeline and trospium chloride) as an additional treatment for adults with schizophrenia.
- The study found that Cobenfy, when added to the patients' existing atypical antipsychotic medications, was able to significantly improve the symptoms of schizophrenia compared to a placebo (a dummy treatment).
- These positive results suggest that Cobenfy could be a promising new treatment option for people with schizophrenia, potentially helping to better manage their symptoms and improve their quality of life.